Exelixis
EXEL
#1697
Rank
A$15.27 B
Marketcap
$53.49
Share price
0.52%
Change (1 day)
65.33%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.43

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.44. In 2022 the company made an earnings per share (EPS) of $0.88 a decrease over its 2021 EPS that were of $1.14.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.43-50.97%
2022$0.88-22.97%
2021$1.14100%
2020$0.57-65.09%
2019$1.63-53.91%
2018$3.53333.96%
2017$0.81-260.61%
2016-$0.51-58.75%
2015-$1.23-42.45%
2014-$2.135.3%
2013-$2.0343.48%
2012-$1.41-264.29%
2011$0.86-165.88%
2010-$1.31-32.54%
2009-$1.93-17.65%
2008-$2.3575.86%
2007-$1.34-25.64%
2006-$1.808.33%
2005-$1.66-42.86%
2004-$2.9030.34%
2003-$2.23-5.23%
2002-$2.35-0.65%
2001-$2.36-51.88%
2000-$4.91

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$5.38 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.88 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.80 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.10 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$21.73 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$21.63 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.86 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$15.36-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.29-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA